Australia markets close in 1 hour 19 minutes

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
109.97+0.03 (+0.03%)
At close: 04:04PM EDT
107.75 -2.22 (-2.02%)
After hours: 05:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close109.94
Bid0.00 x 800
Ask0.00 x 1000
Day's range109.01 - 110.60
52-week range86.34 - 142.64
Avg. volume1,042,619
Market cap19.708B
Beta (5Y monthly)1.29
PE ratio (TTM)40.58
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity

    SOMERSET, N.J., August 09, 2022--Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in Greenville, North Carolina, for $475 million from Mayne

  • Business Wire

    Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast

    SOMERSET, N.J., August 05, 2022--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that it will release financial results for the fourth quarter of fiscal year 2022 ended June 30, 2022, before the market open on Monday, August 29, 2022. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET

  • GlobeNewswire

    Certara Appoints Rosemary Crane as New Independent Board Member

    PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company’s board of directors to eleven members. “We are excited to welcome an accomplished business leader with a proven track record of success join Certara’s Board,” said William F. Feehery, PhD, CEO of Certara. “Rose’s experience in executive leadership